Clinical Data, Inc. to Present at J.P. Morgan Healthcare Conference

NEWTON, Mass.--(BUSINESS WIRE)-- Clinical Data, Inc. (NASDAQ: CLDA) today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a corporate overview at the 29th Annual J.P. Morgan Healthcare Conference. Clinical Data's presentation will take place at 4:30 p.m. PST on Wednesday, January 12, 2011 at The Westin St. Francis hotel, San Francisco, CA.

A live audio and archived webcast of the presentation will be accessible through Clinical Data's website at www.clda.com.

About Clinical Data, Inc.

Clinical Data’s mission is to develop first-in-class and best-in-category therapeutics. The Company is advancing its late-stage drug candidates for central nervous system disorders and cardiovascular diseases, to be followed by promising drug candidates in major therapeutic areas including oncology and inflammatory diseases. To learn more, please visit the Company's website at www.clda.com.



CONTACT:

Clinical Data, Inc.
Theresa McNeely, 617-467-6673
Vice President
Corporate Communications

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.